Where We Are Headed – Featured Research on Bancorp Inc., Northwest Biotherapeutics, Xerium Technologies, and BioPharmX

NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader’s Choice released new research updates concerning several important developing situations including the following equities: Bancorp Inc. (NASDAQ: TBBK), Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Xerium Technologies Inc. (NYSE: XRM) and BioPharmX Corp (NYSE: BPMX). Trader’s Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

To access our full PDF Research Packages for free, please visit the links below.

============

Full PDF DOWNLOAD Links

(You may have to copy and paste the links into your browser)

TBBK Research Package: http://www.traders-choice.com/pdf?s=TBBK

NWBO Research Package: http://www.traders-choice.com/pdf?s=NWBO

XRM Research Package: http://www.traders-choice.com/pdf?s=XRM

BPMX Research Package: http://www.traders-choice.com/pdf?s=BPMX

============

Highlights from today’s reports include:

On Tuesday, December 15, 2015, Nasdaq Composite ended at 4,995.36, up 0.87%, Dow Jones Industrial Average advanced 0.90%, to finish the day at 17,524.91, and the S&P 500 closed at 2,043.41, up 1.06%.

– The stock of Bancorp Inc. lost 0.30% to close Tuesday’s session at USD 6.63. The shares of the company moved in the range of USD 6.46 and USD 6.69 marking a new 52-week low during the session. A trading volume of 0.23 million shares was recorded, which was greater than its 150-day daily average volume of 0.19 million shares and its 52-week average volume of 0.20 million shares. Over the last five days Bancorp Inc.’s shares have declined by 11.24% and in the past one month the stock has lost 13.45%. Additionally, over the last three months the stock has declined 15.97% and in the past six months the shares have registered a loss of 34.29%. The stock is trading at a price to book ratio of 0.80, which compares to a historical PB ratio near to 1.29. Further, the stock is trading at a price to sales ratio of 1.88.

– Northwest Biotherapeutics Inc.’s stock increased by 3.56% to close Tuesday’s session at USD 4.07. The company’s shares fluctuated in the range of USD 3.84 and USD 4.19. A total of 0.38 million shares exchanged hands, which was lesser than its 50-day daily average volume of 0.48 million shares and its 52-week average volume of 0.57 million shares. Over the last three days Northwest Biotherapeutics Inc.’s shares have declined by 8.33% and in the past one week the stock has moved down 1.57%. Additionally, over the last three months the stock has lost 48.35% and in the past six months the shares have shed 59.74%. The stock is trading at a price to sales ratio of 207.65. Northwest Biotherapeutics Inc. has a RSI of 42.78 and is trading 18.13% below its 50-day simple moving average.

– Xerium Technologies Inc.’s stock declined 1.05% to close Tuesday’s session at USD 11.35. The share price vacillated between USD 11.20 and USD 11.65. The stock’s recorded trading volume of 0.13 million shares was above its 50-day and 52-week average volumes which stood at 0.04 million shares each. Over the last three days Xerium Technologies Inc.’s shares have declined by 4.94% and in the past one week the stock has moved down 0.44%. Moreover, in the last six months the stock has lost 36.24% and year to date the shares have shed 28.07%. Further, the company is trading at a price to earnings ratio of 13.59. Additionally, the stock is trading at a price to cash flow ratio of 4.41 and price to sales ratio of 0.36. The stock is trading 11.11% below its 50-day simple moving average and its RSI stood at 36.74.

– BioPharmX Corp’s stock edged lower by 18.83% to close Tuesday’s session at USD 1.81. The company’s shares oscillated between USD 1.61 and USD 2.07. The stock recorded a trading volume of 0.84 million shares, which was well above its 50-day daily average volume of 0.29 million shares and its 52-week average volume of 0.09 million shares. Over the last three days BioPharmX Corp’s shares have advanced 57.39% and in the past one week the stock has moved up 56.03%. Furthermore, over the last three months the stock has gained 0.56% while in the past six months the shares have shed 54.75%. On a compounded total return basis, the company has returned 56.03% in the past one week, and 58.77% in the past one month. With a RSI of 63.77, the stock is trading 43.48% and 1.46% above its 20-day and 200-day simple moving averages, respectively.

About Trader’s Choice:

Trader’s Choice (“TC”) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TC has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the “Production Team”) in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.

NO WARRANTY

TC, the Author and the Reviewer (collectively referred to as the “Publishers”) are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.

RESTRICTIONS

TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:
E-mail: press (at) traders-choice.com

SOURCE: Trader’s Choice

ReleaseID: 434797